Biodesix Closes Series D Financing - July 2011
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
×
254 Results
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.
Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).
Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.
Biodesix announces the U.S. commercial availability of VeriStrat.
Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA
The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.